WO2012116989A1 - Substituted heteroaryl 2', 3', 7', 7a' - tetrahydrospiro-[pyrrole-3, 6' - pyrrolo [1, 2-c] imidazole] - 1', 2 (1h, 5'h) -diones as anticancer agents - Google Patents

Substituted heteroaryl 2', 3', 7', 7a' - tetrahydrospiro-[pyrrole-3, 6' - pyrrolo [1, 2-c] imidazole] - 1', 2 (1h, 5'h) -diones as anticancer agents Download PDF

Info

Publication number
WO2012116989A1
WO2012116989A1 PCT/EP2012/053369 EP2012053369W WO2012116989A1 WO 2012116989 A1 WO2012116989 A1 WO 2012116989A1 EP 2012053369 W EP2012053369 W EP 2012053369W WO 2012116989 A1 WO2012116989 A1 WO 2012116989A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
pyrrolo
chloro
group
aryl
Prior art date
Application number
PCT/EP2012/053369
Other languages
French (fr)
Inventor
David Joseph Bartkovitz
Xin-Jie Chu
Qingjie Ding
Nan Jiang
Jin-Jun Liu
Zhuming Zhang
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of WO2012116989A1 publication Critical patent/WO2012116989A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'- pyrrolo[l,2-c]imidazole]- ,2(lH,5'H)-dione derivatives which act as inhibitors of MDM2-p53 interactions and are useful in the amelioration or treatment of cancer.
  • p53 is a tumor suppresser protein that plays a central role in protection against development of cancer. It guards cellular integrity and prevents the propagation of permanently damaged clones of cells by the induction of growth arrest or apoptosis.
  • p53 is a transcription factor that can activate a panel of genes implicated in the regulation of cell cycle and apoptosis.
  • p53 is a potent cell cycle inhibitor which is tightly regulated by MDM2 at the cellular level. MDM2 and p53 form a feedback control loop. MDM2 can bind p53 and inhibit its ability to transactivate p53-regulated genes. In addition, MDM2 mediates the ubiquitin-dependent degradation of p53.
  • MDM2 can activate the expression of the MDM2 gene, thus raising the cellular level of MDM2 protein.
  • This feedback control loop insures that both MDM2 and p53 are kept at a low level in normal proliferating cells.
  • MDM2 is also a cofactor for E2F, which plays a central role in cell cycle regulation.
  • MDM2 protein degradation Inhibition of MDM2-p53 interaction in tumor cells with wild-type p53 should lead to accumulation of p53, cell cycle arrest and/or apoptosis. MDM2 antagonists, therefore, can offer a novel approach to cancer therapy as single agents or in combination with a broad spectrum of other antitumor therapies. The feasibility of this strategy has been shown by the use of different macromolecular tools for inhibition of MDM2-p53 interaction (e.g.
  • MDM2 also binds E2F through a conserved binding region as p53 and activates E2F-dependent transcription of cyclin A, suggesting that MDM2 antagonists might have effects in p53 mutant cells.
  • the present invention relates to substituted heteroaryl 2',3',7',7a'- tetrahydrospiro[pyrrole-3,6'-pyrrolo[l,2-c]imidazole]- ,2(lH,5'H)-dione derivatives of formula I which act as antagonists of MDM2 interactions and hence are useful as potent and selective anticancer agents.
  • compounds of the formula I which act as antagonists of MDM2 interactions and hence are useful as potent and selective anticancer agents.
  • R 6 is selected from the group consisting of H, F, CI, Br, I, CN, N0 2 , ethynyl, cyclopropyl, lower alkyl, vinyl and alkoxy,
  • R 7 is selected from the group consisting of H, F, CI, methyl
  • R 8 is selected from the group consisting of H, F, CI, methyl
  • R9 is selected from the group consisting of H, F, CI, methyl
  • Ri is independently selected from the group consisting of lower alkyl
  • substituted lower alkyl lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl;
  • R 2 is selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;
  • R 3 is selected from the group consisting of (CH 2 ) n -R ⁇ (CH 2 ) n -NR'R", (CH 2 ) n -NR'COR", (CH 2 ) n -NR'S0 2 R", (CH 2 ) n -COOH, (CH 2 ) n -COOR', (CH 2 ) n -CONR'R", (CH 2 ) n -OR', (CH 2 ) n -SR', (CH 2 ) n -SOR', (CH 2 ) n -S0 2 R', (CH 2 ) n -COR ⁇ (CH 2 ) n -S0 3 H, (CH 2 ) n -SONR'R", (CH 2 ) n - S0 2 NR'R", (CH 2 CH 2 0) m
  • n and p are independently 0 to 6;
  • R 4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R 4 and R5 can be combined to form an oxo or thio group;
  • Another embodiment of the invention relates to compounds of formula I having a stereochemical structure shown as formula II
  • R 6 is selected from the group consisting of H, F, CI, Br, I,, CN, N0 2 , ethynyl, cyclopropyl, lower alkyl, vinyl and alkoxy;
  • R 7 is selected from the group consisting of H, F, CI, methyl
  • R 8 is selected from the group consisting of H, F, CI, methyl
  • R9 is selected from the group consisting of H, F, CI, methyl
  • Ri is independently selected from the group consisting of lower alkyl
  • substituted lower alkyl lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl;
  • R 2 is selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;
  • R 3 is selected from the group consisting of (CH 2 ) n -R ⁇ (CH 2 ) n -NR'R", (CH 2 ) n -NR'COR", (CH 2 ) n -NR'S0 2 R", (CH 2 ) n -COOH, (CH 2 ) n -COOR ⁇ (CH 2 ) n -CONR'R", (CH 2 ) admir-OR ⁇ (CH 2 ) admir-SR ⁇ (CH 2 ) n -SOR ⁇ (CH 2 ) n -S0 2 R ⁇ (CH 2 ) n -COR', (CH 2 ) n -S0 3 H, (CH 2 ) n -SONR'R", (CH 2 ) n - S0 2 NR'R", (CH 2 CH 2 0) m -(CH 2 ) n -R', (CH 2 CH 2 0) m -(CH 2 ) n -OH, (CH 2
  • n and p are independently 0 to 6;
  • R 4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R 4 and R5 can be combined to form an oxo or thio group;
  • Rio and Rn are both methyl, or alternatively, Rio and Rn together with the carbon to which they are attached form a ring selected from cyclopropyl, cyclobutyl, cyclopentyl or acyclohexyl ;
  • Ri 2 is (CH 2 ) q -Ri 3, where q is 0, 1 or 2 and
  • Ri 3 is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle and substituted heterocycle.
  • R 6 is selected from F, CI or Br
  • R 7 , R 8, R9 are hydrogen
  • R 2 is selected from the group consisting of aryl, aryl substitued with CI or F or Br, and heteroaryl optionally substituted with H, F or CI or Br;
  • Ri is a substituted lower alkyl of the formula
  • Rio and Rn are both methyl, or alternatively, Rio and Rn together with the carbon to which they are attached form a ring selected from cyclopropyl, cyclobutyl, cyclopentyl or acyclohexyl;
  • R 12 is (CH 2 ) q -Ri 3, where q is 0, 1 or 2;
  • Ri 3 is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle and substituted heterocycle;
  • R 3 is (CH 2 ) prison-R' ; n is 0 or 1 and
  • R' is selected from aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle or substituted heterocycle;
  • R 4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R 4 and R5 can be combined to form an oxo or thio group;
  • R 6 is selected from F, CI or Br
  • R 7 , R 8 , R9 are hydrogen
  • R 2 is selected from the group consisting wherein
  • Ri 4 is F, CI or Br
  • Ri5 is H or F
  • Ri is a substituted lower alkyl of the formula
  • Rio and Rn are both methyl, or alternatively, Rio and Rn together with the carbon to which they are attached form a ring selected from cyclopropyl, cyclobutyl, cyclopentyl or acyclohexyl;
  • Rn is (CH 2 ) q -Ri 3 , where q is 0, 1 or 2;
  • Ri3 is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle and substituted heterocycle;
  • R 3 is (CH 2 ) n -R' ;
  • n 0 or 1 ;
  • R' is selected from aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle or substituted heterocycle;
  • R 4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R 4 and R5 can be combined to form an oxo or thio group;
  • R 6 is selected from hydrogen, -C(l-6) alkyl, -0-C(l-6) alkyl and halogen; and Ri is neopentyl;
  • R 3 is phenyl, which is substituted with one or two substituents independently selected from -0-C(l-6) alkyl, -C(0)-NH 2 and -C(0)-OH;
  • R4 and R5 are independently selected from hydrogen and -C(l-6) alkyl, which alkyl is not substituted or substituted with a substituent selected from hydroxyl and tetrahydropyranyl; and pharmaceutically acceptable salts thereof.
  • R4 and R5 are independently selected from hydrogen and -C(l-6) alkyl, which alkyl is not substituted or substituted with a substituent selected from hydroxyl and tetrahydropyranyl; and pharmaceutically acceptable salts thereof.
  • R 6 is selected from hydrogen, -C(l-6) alkyl, -0-C(l-6) alkyl and halogen.
  • a benzodioxyl group halogen, hydroxy, CN, CF 3 , NH 2 , N(H, lower-alkyl), N(lower-alkyl)2, aminocarbonyl, carboxy, N0 2 , lower-alkoxy, thio-lower-alkoxy, lower-alkylsufonyl, aminosulfonyl, lower-alkylcarbonyl, lower-alkylcarbonyloxy, lower-alkoxycarbonyl, lower-alkyl-carbonyl-NH, fluoro-lower-alkyl, fluoro-lower-alkoxy, lower-alkoxy-carbonyl-lower-alkoxy, carboxy-lower-alkoxy, carbamoyl- lower-alkoxy, hydroxy-lower-alkoxy, NH 2 -lower-alkoxy, N(H, lower-alkyl)-lower-alkoxy, N(lower-alkyl) 2 -lower
  • sulfonylaminocarbonyl lower-alkyl sulfonylaminocarbonyl-aryl, hydroxycarbamoyl-phenyl, benzyloxy-lower-alkoxy, mono- or di-lower alkyl substituted amino-sulfonyl and lower-alkyl which can optionally be substituted with halogen, hydroxy, NH 2 , N(H, lower-alkyl) or N(lower- alkyl) 2. .
  • Preferred substituents for the cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycle rings are halogen, lower alkoxy, lower alkyl, hydroxycarbonyl, carboxy, carboxy lower alkoxy, oxo and CN.
  • Preferred substituents for alkyl are alkoxy and N(lower alkyl) 2 .
  • substituted as in substituted alkyl, means that the substitution can occur at one or more positions and, unless otherwise indicated, that the substituents at each substitution site are independently selected from the specified options.
  • optionally substituted refers to the fact that one or more hydrogen atoms of a chemical group (with one or more hydrogen atoms) can be, but does not necessarily have to be, substituted with another substituent. In the specification where indicated the various groups may be substituted by preferably, 1-3
  • substituents independently selected from the group consisting of H, carboxyl, amido, hydroxyl, alkoxy, substituted alkoxy, sulfide, sulfone, sulfonamide, sulfoxide, halogen, nitro, amino, substituted amino, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl, substituted lower cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle;
  • alkyl refers to straight- or branched-chain saturated hydrocarbon groups having from 1 to about 20 carbon atoms, including groups having from 1 to 7 carbon atoms. In certain embodiments, alkyl substituents may be lower alkyl substituents.
  • lower alkyl refers to alkyl groups having from 1 to 6 carbon atoms, and in certain embodiments from 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl,
  • cycloalkyl is intended to refer to any stable monocyclic or polycyclic system which consists of carbon atoms only, any ring of which being saturated
  • cycloalkenyl is intended to refer to any stable monocyclic or polycyclic system which consists of carbon atoms only, with at least one ring thereof being partially unsaturated.
  • cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, bicycloalkyls, including bicyclooctanes such as
  • cycloalkenyls include, but are not limited to, cyclopentenyl or cyclohexenyl.
  • alkenyl as used herein means an unsaturated straight-chain or branched aliphatic hydrocarbon group containing one double bond and having 2 to 6, preferably 2 to 4 carbon atoms.
  • alkenyl group examples include vinyl, ethenyl, allyl, isopropenyl, 1-propenyl, 2- methyl-l-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-l-butenyl, 3-methyl-2-butenyl, 1- pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3- hexenyl, 4-hexenyl and 5-hexenyl.
  • alkynyl as used herein means an unsaturated straight-chain or branched aliphatic hydrocarbon group containing one triple bond and having 2 to 6, preferably 2 to 4 carbon atoms.
  • alkynyl group examples are ethynyl, 1-propynyl, 2-propynyl, 1-butynyl,
  • halogen as used in the definitions means fluorine, chlorine, bromine, or iodine, preferably fluorine and chlorine.
  • Aryl means a monovalent, monocyclic or bicyclic, aromatic carbocyclic
  • heteroaryl means an aromatic heterocyclic ring system containing up to two rings.
  • Preferred heteroaryl groups include, but are not limited to, thienyl, furyl, indolyl, pyrrolyl, pyridinyl, pyrazinyl, oxazolyl, thiaxolyl, quinolinyl, pyrimidinyl, imidazole and tetrazolyl.
  • aryl or heteroaryl which are bicyclic it should be understood that one ring may be aryl while the other is heteroaryl and both being substituted or unsubstituted.
  • Heterocycle means a substituted or unsubstituted 5 to 8 membered, mono- or bicyclic, non-aromatic hydrocarbon, wherein 1 to 3 carbon atoms are replaced by a hetero atom selected from nitrogen, oxygen or sulfur atom. Examples include pyrrolidin-2-yl; pyrrolidin-3-yl;
  • Hetero atom means an atom selected from N, O and S.
  • Alkoxy, alkoxyl or lower alkoxy refers to any of the above lower alkyl groups attached to an oxygen atom.
  • Typical lower alkoxy groups include methoxy, ethoxy, isopropoxy or propoxy, butyloxy and the like.
  • Further included within the meaning of alkoxy are multiple alkoxy side chains, e.g. ethoxy ethoxy, methoxy ethoxy, methoxy ethoxy ethoxy and the like and substituted
  • alkoxy side chains e.g., dimethylamino ethoxy, diethylamino ethoxy, dimethoxy-phosphoryl methoxy and the like.
  • “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
  • “Pharmaceutically acceptable salt” refers to conventional acid-addition salts or base- addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
  • Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, trifluoro acetic acid and the like.
  • Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide.
  • Chemical modification of a pharmaceutical compound (i.e. drug) into a salt is a technique well known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See, e.g., Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196 and 1456- 1457.
  • the compounds of formula I and II as well as their salts that have at least one
  • asymmetric carbon atom may be present as racemic mixtures or different stereoisomers.
  • the various isomers can be isolated by known separation methods, e.g., chromatography.
  • the compounds of the present invention are useful in the treatment or control of cell proliferative disorders, in particular oncological disorders. These compounds and formulations containing said compounds may be particularly useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors.
  • a therapeutically effective amount of a compound in accordance with this invention means an amount of compound that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is within the skill in the art.
  • the therapeutically effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art.
  • Such dosage will be adjusted to the individual requirements in each particular case including the specific compound(s) being administered, the route of administration, the condition being treated, as well as the patient being treated.
  • the daily dosage can be administered as a single dose or in divided doses, or for parenteral administration; it may be given as continuous infusion.
  • Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, as well as the particular mode of administration.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of a formula I compound which produces a therapeutic effect.
  • this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
  • Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, sachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non- aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
  • a compound of the present invention may also be administered as a bolus, electuary or paste.
  • Effective amount means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
  • IC50 refers to the concentration of a particular compound required to inhibit 50% of a specific measured activity. IC 5 0 can be measured, inter alia, as is described subsequently.
  • the present invention provides novel methods for the synthesis of the substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'-pyrrolo[l,2-c]imidazole]- ,2(lH,5'H)-dione derivatives of formula I or II.
  • Compounds of this invention can be synthesized according to the following general schemes. The detailed processes for synthesizing these compounds are provided in the examples.
  • An intermediate III can be made from a base-catalyzed condensation reaction of appropriately selected substituted 4- or 5- or 6- or 7-aza-2-oxindole I and appropriate substituted aldehyde II in methanol (Scheme 1).
  • the choice of bases includes but is not limited to pyrrolidine or piperidine.
  • the reaction generates III as a mixture of Z- and E-isomers with E- isomer as the major product.
  • intermediates V or VII can be made from an acid-catalyzed condensation reaction of appropriately selected substituted 5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one IV or 4,6-dihydro-thieno[3,2-b]pyrrol-5-one VI and aldehyde II in hydrochloric and acetic aicd (M. Cheung et al, Tetrahedron Lett. 2001, 42, 999) (Scheme 2).
  • Racemic synthesis of compounds XI and XII can be achieved as outlined in Scheme 4.
  • Amine R 3 NH 2 can be reacted with N-protected glycine like N-Boc glycine by using a coupling reagent like EDCI or HATU to give intermediate VIII.
  • Intermediate VIII can be treated with trifluoroacetic acid or HC1 at room temperature to remove protective Boc group and give intermediate IX.
  • Appropriately selected aldehyde RiCHO can react with IX to give the imine X.
  • Intermediate III or V or VII can be protected with Boc group to give intermediate XIII.
  • the cylcoaddition reaction between intermediates X and XIII mediated by LiOH or LiCl/DABCO follow by reaction to remove Boc group by trifluroacetic aicd give compounds XI.
  • Compounds XI can be subsequently separated into oprically pure or enriched chiral compounds XII.
  • Step a To a solution of chiral (2S,3R,4S,5R)-N-(4-carbamoyl-2-methoxyphenyl)-6'- chloro-4-(3 -chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- 1 ',2'-dihydrospiro[pyrrolidine-3 ,3 '- pyrrolo[3,2-c]pyridine]-5-carboxamide (24 mg, 0.039 mmol) and acetic acid (0.4 mL) in dichloromethane (0.4 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (27 mg, 0.02 mL, 0.336 mmol).
  • Step b The above crude chiral 4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide (24 mg, 0.037 mmol) was mixed with EtOH (3 mL) and treated with a solution of 2N NaOH (0.53 mL, 1.06 mmol).
  • Step a To a solution of methyl rac-4-((2S,3R,4S,5R)-4-(3-chloro-2-fluorophenyl)-6'- methyl-2-neopentyl-2'-oxo- ,2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2-c]pyridine]-5- ylcarboxamido)-3-methoxybenzoate (46 mg, 0.0762 mmol) and acetic acid (0.55 mL) in dichloromethane (0.6 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (33 mg, 0.03 mL, 0.403 mmol).
  • Step b The above crude methyl rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-l'- (hydroxymethyl)-6'-methyl-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (61 mg, 0.0762 mmol) was mixed with EtOH (6 mL) and treated with a solution of 2N NaOH (1.0 mL, 2.00 mmol).
  • Step a To a solution of methyl rac-4-((2S,3S,4S,5R)-4-(3-chloro-2-fluorophenyl)-2- neopentyl-2'-oxo-1 ⁇ 2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2-b]pyridine]-5-ylcarboxamido)- 3-methoxybenzoate (50 mg, 0.084 mmol) and acetic acid (0.7 mL) in dichloromethane (0.7 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (44 mg, 0.04 mL, 0.53 mmol).
  • Step b The above crude crude methyl rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-b]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (52 mg, 0.082 mmol) was dissolved in MeOH (4 mL) and treated with a solution of 2N NaOH (0.7 mL, 1.40 mmol).
  • reaction mixture was heated to 50 °C and stirred for 5 hr when LCMS showed the reaction was complete.
  • the reaction mixture was neutralized with IN HCl (1.4 mL to pH 6) and diluted with EtOAc (75 mL), washed with H20 (3x15 mL), concentrated.
  • Step a To a solution of methyl rac-4-((2S,3R,4S,5R)-4-(3-chloro-2-fluorophenyl)-2- neopentyl-2'-oxo-1 ⁇ 2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2-c]pyridine]-5-ylcarboxamido)- 3-methoxybenzoate (40 mg, 0.067 mmol) and acetic acid (0.5 mL) in dichloromethane (0.5 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (27 mg, 0.025 mL, 0.34 mmol).
  • Step b The above crude crude methyl rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (58 mg, 0.067 mmol) was dissolved in EtOH (5 mL) and treated with a solution of 2N NaOH (0.9 mL, 1.80 mmol).
  • Step a To a solution of methyl 4-((2S,3R,4S,5R)-4-(3-chloro-2-fluorophenyl)-6'- methoxy-2-neopentyl-2'-oxo-1 ⁇ 2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2-c]pyridine]-5- ylcarboxamido)-3-methoxybenzoate (45 mg, 0.072 mmol) and acetic acid (0.52 mL) in dichloromethane (0.5 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (32 mg, 0.030 mL, 0.40 mmol).
  • Step b The above crude methyl 4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-l'- (hydroxymethyl)-6'-methoxy-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (86 mg, 0.072 mmol) was dissolved in EtOH (5 mL) and treated with a solution of 2N NaOH (0.95 mL, 1.90 mmol).
  • Ammonium hydroxide (108 mg, 0.12 mL, 0.912 mmol) was added and the mixture was stirred for 20 min. The mixture was partitioned between EtOAc (75 mL) and water (10 mL), washed with sat. NaHC0 3 (10 mL), water (10 mL) then sat. NH 4 C1 (10 mL). The organic layer was dried over Na 2 S0 4 and concentrated in vacuo onto silica gel.
  • Step a To a solution of rac-(2S,3R,4S,5R)-N-(4-carbamoyl-3-methoxyphenyl)-4-(3- chloro-2-fluorophenyl)-2-neopentyl-2'-oxo-r,2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2- c]pyridine]-5-carboxamide (20.7 mg, 0.035 mmol) and acetic acid (0.3 mL) in dichloromethane (0.5 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (22 mg, 0.020 mL, 0.27 mmol).
  • Step b The above crude rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-l'- (hydroxymethyl)-5-neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'- pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-2-methoxybenzamide (23.9 mg, 0.035 mmol) was dissolved in EtOH (5 mL) and treated with a solution of 2N NaOH (0.48 mL, 0.96 mmol).
  • Step a To a solution of rac-methyl 4-((2S,3R,4S,5R)-6'-chloro-4-(3-chloro-2- fluorophenyl)-2-neopentyl-2'-oxo-l ⁇ 2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[2,3-b]pyridine]-5- ylcarboxamido)-3-methoxybenzoate (45 mg, 0.071 mmol) and acetic acid (0.52 mL) in dichloromethane (0.5 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (32 mg, 0.030 mL, 0.40 mmol).
  • Step b The above crude rac-methyl 4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (48 mg, 0.071 mmol) was dissolved in EtOH (5 mL) and treated with a solution of 2N NaOH (0.96 mL, 1.92 mmol).
  • Step a To a solution of chiral (2S,3R,4S,5R)-N-(4-carbamoyl-2-methoxyphenyl)-6'- chloro-4-(3-chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- ,2'-dihydrospiro[pyrrolidine-3,3'- pyrrolo[3,2-c]pyridine]-5-carboxamide (21 mg, 0.034 ⁇ mmol) and acetic acid (0.5 mL) in dichloromethane (0.5 mL), was added acetaldehyde (27.5 mg, 0.035 mL, 0.624 mmol).
  • Step b The above crude chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)- 1 '-( 1 -hydroxyethyl)-3-methyl-5-neopentyl- 1 ,2'-dioxo- 1 ',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (87 mg, 0.034 mmol) was mixed with EtOH (3 mL) and treated with a solution of 2N NaOH (0.46 mL, 0.92 mmol).
  • Step a To a solution of chiral (2S,3R,4S,5R)-N-(4-carbamoyl-2-methoxyphenyl)-6'- chloro-4-(3-chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- ,2'-dihydrospiro[pyrrolidine-3,3'- pyrrolo[3,2-c]pyridine]-5-carboxamide (20 mg, 0.033 ⁇ mmol) and acetic acid (0.5 mL) in dichloromethane (0.5 mL), was added propionaldehyde (40 mg, 0.67 mmol).
  • Step b The above crude chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)-3 -ethyl- 1 '-( 1 -hydroxypropyl)-5-neopentyl- 1 ,2'-dioxo- 1 ',2' ,7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (44.5 mg, 0.033 mmol) was mixed with EtOH (3 mL) and treated with a solution of 2N NaOH (0.46 mL, 0.92 mmol).
  • Step a To a solution of chiral (2S,3R,4S,5R)-N-(4-carbamoyl-2-methoxyphenyl)-6'- chloro-4-(3-chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- ,2'-dihydrospiro[pyrrolidine-3,3'- pyrrolo[3,2-c]pyridine]-5-carboxamide (29.7 mg, 0.048 mmol) and acetic acid (1 mL) in dichloromethane (1 mL) in a microwave vial, was added Tert-butyldimethylsilyloxy
  • Step b The above crude chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)- 1 '-( 1 ,2-dihydroxyethyl)-3-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- 1 ',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (162 mg) was mixed with EtOH (3 mL) and treated with a solution of 2N NaOH (0.65 mL, 1.3 mmol).
  • reaction mixture was heated to 50 °C and stirred for 1 hr when LCMS showed the reaction was complete.
  • the reaction mixture was poured into EtOAc (20 mL), washed with water (10 mL) and concentrated.
  • the crude product was purified by flash
  • Step a To a solution of chiral (2S,3R,4S,5R)-N-(4-carbamoyl-2-methoxyphenyl)-6'- chloro-4-(3-chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- ,2'-dihydrospiro[pyrrolidine-3,3'- pyrrolo[3,2-c]pyridine]-5-carboxamide ((21 mg, 0.034 mmol) and acetic acid (1 mL) in dichloromethane (1 mL) in a microwave vial, was added 3-(TETRAHYDRO-2H-PYRAN-4- YL)PROPANAL (24 mg, 0.169 mmol, Biofine Product List).
  • Step b The above crude chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)-l'-(l-hydroxy-3-(tetrahydro-2H-pyran-4-yl)propyl)-5-neopentyl-l,2'-dioxo-3-(2- (tetrahydro-2H-pyran-4-yl)ethyl)- r,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2-c]imidazole-6,3'- pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide (33.1 mg) was mixed with EtOH (3 mL) and treated with a solution of 2N NaOH (0.47 mL, 0.94 mmol).
  • Test is performed in black flat-bottom 384-well plates (Costar) in a total volume of 40 uL containing:90 nM biotinylate peptide, 160 ng/ml GST-MDM2, 20 nM streptavidin-APC (PerkinElmerWallac), 2 nM Eu-labeled anti- GST- antibody (PerkinElmerWallac), 0.2% bovine serum albumin (BSA), 1 mM dithiothreitol (DTT) and 20 mM Tris-borate saline (TBS) buffer as follows: Add 10 uL of GST-MDM2 (640 ng/ml working solution) in reaction buffer to each well.
  • BSA bovine serum albumin
  • DTT dithiothreitol
  • TBS Tris-borate saline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There are provided compounds of the formula (I), wherein A, B, V, W, R1, R2, R3, R4 and R5 are described herein, together with the enantiomers and pharmaceutically acceptable salts and esters thereof, methods of making those compounds, pharmaceutical compositions comprising them, as well as their use as anticancer agents, and which function as inhibitors of the interaction between p53 and MDM2.

Description

SUBSTITUTED HETEROARYL 2 ' , 3 ' , 7 ' , 7A ' - TETRAHYDROSPIRO -
[PYRROLE-3 , 6 ' - PYRROLO [1 , 2 -C] IMIDAZOLE] - 1 ' , 2 (1H, 5 ' H) -DIONES AS ANTICANCER AGENTS
The present invention relates to substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'- pyrrolo[l,2-c]imidazole]- ,2(lH,5'H)-dione derivatives which act as inhibitors of MDM2-p53 interactions and are useful in the amelioration or treatment of cancer.
[0001] p53 is a tumor suppresser protein that plays a central role in protection against development of cancer. It guards cellular integrity and prevents the propagation of permanently damaged clones of cells by the induction of growth arrest or apoptosis. At the molecular level, p53 is a transcription factor that can activate a panel of genes implicated in the regulation of cell cycle and apoptosis. p53 is a potent cell cycle inhibitor which is tightly regulated by MDM2 at the cellular level. MDM2 and p53 form a feedback control loop. MDM2 can bind p53 and inhibit its ability to transactivate p53-regulated genes. In addition, MDM2 mediates the ubiquitin-dependent degradation of p53. p53 can activate the expression of the MDM2 gene, thus raising the cellular level of MDM2 protein. This feedback control loop insures that both MDM2 and p53 are kept at a low level in normal proliferating cells. MDM2 is also a cofactor for E2F, which plays a central role in cell cycle regulation.
[0002] The ratio of MDM2 to p53 (E2F) is deregulated in many cancers. Frequently occurring molecular defects in the pl6INK4/pl9ARF locus, for instance, have been shown to affect
MDM2 protein degradation. Inhibition of MDM2-p53 interaction in tumor cells with wild-type p53 should lead to accumulation of p53, cell cycle arrest and/or apoptosis. MDM2 antagonists, therefore, can offer a novel approach to cancer therapy as single agents or in combination with a broad spectrum of other antitumor therapies. The feasibility of this strategy has been shown by the use of different macromolecular tools for inhibition of MDM2-p53 interaction (e.g.
antibodies, antisense oligonucleotides, peptides). MDM2 also binds E2F through a conserved binding region as p53 and activates E2F-dependent transcription of cyclin A, suggesting that MDM2 antagonists might have effects in p53 mutant cells.
JB, 5/1/2012 [0004] The present invention relates to substituted heteroaryl 2',3',7',7a'- tetrahydrospiro[pyrrole-3,6'-pyrrolo[l,2-c]imidazole]- ,2(lH,5'H)-dione derivatives of formula I which act as antagonists of MDM2 interactions and hence are useful as potent and selective anticancer agents. There are provided compounds of the formula
Figure imgf000004_0001
R6 is selected from the group consisting of H, F, CI, Br, I, CN, N02, ethynyl, cyclopropyl, lower alkyl, vinyl and alkoxy,
R7 is selected from the group consisting of H, F, CI, methyl;
R8 is selected from the group consisting of H, F, CI, methyl;
R9 is selected from the group consisting of H, F, CI, methyl;
wherein in the case of (f) A is a bond;
Ri is independently selected from the group consisting of lower alkyl,
substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl;
R2 is selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl; R3 is selected from the group consisting of (CH2)n-R\ (CH2)n-NR'R", (CH2)n-NR'COR", (CH2)n-NR'S02R", (CH2)n-COOH, (CH2)n-COOR', (CH2)n-CONR'R", (CH2)n-OR', (CH2)n-SR', (CH2)n-SOR', (CH2)n-S02R', (CH2)n-COR\ (CH2)n-S03H, (CH2)n-SONR'R", (CH2)n- S02NR'R", (CH2CH20)m-(CH2)n-R\ (CH2CH20)m-(CH2)n-OH, (CH2CH20)m-(CH2)n-OR', (CH2CH20)m-(CH2)n-NR'R", (CH2CH20)m-(CH2)n-NR'COR", (CH2CH20)m-(CH2)n-NR'S02R", (CH2CH20)m-(CH2)n-COOH, (CH2CH20)m-(CH2)n-COOR' , (CH2CH20)m-(CH2)n-CONR'R", (CH2CH20)m-(CH2)n-S02R', (CH2CH20)m-(CH2)n-COR', (CH2CH20)m-(CH2)n-SONR'R", (CH2CH20)m-(CH2)n-S02NR'R", (CH2)p-(CH2CH20)m-(CH2)n-R' , (CH2)P- (CH2CH20)m- (CH2)n-OH, (CH2)p-(CH2CH20)m-(CH2)n-OR', (CH2)p-(CH2CH20)m-(CH2)n-NR'R", (CH2)p- (CH2CH20)m-(CH2)n-NR'COR", (CH2)p-(CH2CH20)m-(CH2)n-NR'S02R", (CH2)p-(CH2CH20)m- (CH2)n-COOH, (CH2)p-(CH2CH20)m-(CH2)n-COOR' , (CH2)p-(CH2CH20)m-(CH2)n-CONR' R", (CH2)p-(CH2CH20)m-(CH2)n-S02R' , (CH2)p-(CH2CH20)m-(CH2)n-COR' , (CH2)p-(CH2CH20)m- (CH2)n-SONR'R", (CH2)p-(CH2CH20)m-(CH2)n-S02NR'R", -COR', -SOR' and S02R' wherein R' and R' ' are independently selected from H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl, substituted lower cycloalkenyl, aryl, substituted aryl, hetereoaryl, substituted hetereoaryl, hetereocycle or substituted hetereocycle or R and R may independently link to form a cyclic structure selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heteroaryl or substituted or
unsubstituted heterocycle;
m, n and p are independently 0 to 6;
one of R4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R4 and R5 can be combined to form an oxo or thio group;
and enantiomers thereof or a pharmaceutically acceptable salt or ester thereof.
[0005] Another embodiment of the invention relates to compounds of formula I having a stereochemical structure shown as formula II
Figure imgf000006_0001
wherein
Figure imgf000006_0002
is selected from the group consisting of
Figure imgf000006_0003
R6 is selected from the group consisting of H, F, CI, Br, I,, CN, N02, ethynyl, cyclopropyl, lower alkyl, vinyl and alkoxy;
R7 is selected from the group consisting of H, F, CI, methyl;
R8 is selected from the group consisting of H, F, CI, methyl;
R9 is selected from the group consisting of H, F, CI, methyl;
wherein in the case of (f) A is a bond;
Ri is independently selected from the group consisting of lower alkyl,
substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl;
R2 is selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;
R3 is selected from the group consisting of (CH2)n-R\ (CH2)n-NR'R", (CH2)n-NR'COR", (CH2)n-NR'S02R", (CH2)n-COOH, (CH2)n-COOR\ (CH2)n-CONR'R", (CH2)„-OR\ (CH2)„-SR\ (CH2)n-SOR\ (CH2)n-S02R\ (CH2)n-COR', (CH2)n-S03H, (CH2)n-SONR'R", (CH2)n- S02NR'R", (CH2CH20)m-(CH2)n-R', (CH2CH20)m-(CH2)n-OH, (CH2CH20)m-(CH2)n-OR\ (CH2CH20)m-(CH2)n-NR'R", (CH2CH20)m-(CH2)n-NR'COR", (CH2CH20)m-(CH2)n-NR'S02R", (CH2CH20)m-(CH2)n-COOH, (CH2CH20)m-(CH2)n-COOR' , (CH2CH20)m-(CH2)n-CONR'R", (CH2CH20)m-(CH2)n-S02R', (CH2CH20)m-(CH2)n-COR', (CH2CH20)m-(CH2)n-SONR'R", (CH2CH20)m-(CH2)n-S02NR'R", (CH2)p-(CH2CH20)m-(CH2)n-R' , (CH2)P- (CH2CH20)m- (CH2)n-OH, (CH2)p-(CH2CH20)m-(CH2)n-OR' , (CH2)p-(CH2CH20)m-(CH2)n-NR'R", (CH2)p- (CH2CH20)m-(CH2)n-NR'COR", (CH2)p-(CH2CH20)m-(CH2)n-NR'S02R", (CH2)p-(CH2CH20)m- (CH2)n-COOH, (CH2)p-(CH2CH20)m-(CH2)n-COOR' , (CH2)p-(CH2CH20)m-(CH2)n-CONR' R", (CH2)p-(CH2CH20)m-(CH2)n-S02R' , (CH2)p-(CH2CH20)m-(CH2)n-COR' , (CH2)p-(CH2CH20)m- (CH2)n-SONR'R", (CH2)p-(CH2CH20)m-(CH2)n-S02NR'R", -COR', -SOR' and S02R' wherein R' and R" are independently selected from H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl, substituted lower cycloalkenyl, aryl, substituted aryl, hetereoaryl, substituted hetereoaryl, hetereocycle or substituted hetereocycle or R and R may independently link to form a cyclic structure selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heteroaryl or substituted or
unsubstituted heterocycle;
m, n and p are independently 0 to 6;
one of R4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R4 and R5 can be combined to form an oxo or thio group;
and enantiomers thereof or a pharmaceutically acceptable salt or ester thereof.
[0006] Preferred are compounds of Formula I including compounds of Formula II or a pharmaceutically acceptable salt thereof wherein R6 is F, CI or Br.
[0007] Preferred are compounds of Formula I including compounds of Formula II or a pharmaceutically acceptable salt thereof wherein R7 , R8i R9 are all hydrogen. [0008] Preferred are compounds of Formula I including compounds of Formula II or a pharmaceutically acceptable salt thereof wherein R2 is selected from the group consisting of aryl, aryl substitued with CI or F or Br and heteroaryl optionally substituted with H, F, CI or Br.
[0010] Preferred are compounds of Formula I including compounds of Formula II or a pharmaceutically acceptable salt thereof wherein Ri is a substituted lower alkyl of the formula
Figure imgf000008_0001
where Rio and Rn are both methyl, or alternatively, Rio and Rn together with the carbon to which they are attached form a ring selected from cyclopropyl, cyclobutyl, cyclopentyl or acyclohexyl ;
Ri2 is (CH2)q-Ri3, where q is 0, 1 or 2 and
Ri3 is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle and substituted heterocycle.
[0011] Preferred are compounds of Formula I including compounds of Formula II or a pharmaceutically acceptable salt thereof wherein one of R3 is (CH2)n-R\ n is 0 or 1 and R' is aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle or substituted heterocycle.
[0012] Preferred are compounds of Formula I including compounds of Formula II or a pharmaceutically acceptable salt thereof wherein
R6 is selected from F, CI or Br;
R7 , R8, R9 are hydrogen;
R2 is selected from the group consisting of aryl, aryl substitued with CI or F or Br, and heteroaryl optionally substituted with H, F or CI or Br;
Ri is a substituted lower alkyl of the formula
R10
where Rio and Rn are both methyl, or alternatively, Rio and Rn together with the carbon to which they are attached form a ring selected from cyclopropyl, cyclobutyl, cyclopentyl or acyclohexyl;
R12 is (CH2)q-Ri3, where q is 0, 1 or 2;
Ri3 is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle and substituted heterocycle;
R3 is (CH2)„-R' ; n is 0 or 1 and
R' is selected from aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle or substituted heterocycle;
one of R4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R4 and R5 can be combined to form an oxo or thio group;
and enantiomers thereof or a pharmaceutically acceptable salt, or ester thereof. [0013] Further preferred are compounds of Formula II
wherein
Figure imgf000009_0001
is selected from the group consisting of
Figure imgf000009_0002
R6 is selected from F, CI or Br;
R7, R8, R9 are hydrogen;
R2 is selected from the group consisting
Figure imgf000010_0001
wherein
Ri4 is F, CI or Br;
Ri5 is H or F;
Ri is a substituted lower alkyl of the formula
Figure imgf000010_0002
where Rio and Rn are both methyl, or alternatively, Rio and Rn together with the carbon to which they are attached form a ring selected from cyclopropyl, cyclobutyl, cyclopentyl or acyclohexyl;
Rn is (CH2)q-Ri3, where q is 0, 1 or 2;
Ri3 is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle and substituted heterocycle;
R3 is (CH2)n-R' ;
n is 0 or 1 ;
R' is selected from aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle or substituted heterocycle;
one of R4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R4 and R5 can be combined to form an oxo or thio group;
or a pharmaceutically acceptable salt thereof. In one embodiment there are provided the compounds of the formula (II)
Figure imgf000011_0001
II wherein
Figure imgf000011_0002
is selected from the group consisting of
Figure imgf000011_0003
and
whereby,
R6 is selected from hydrogen, -C(l-6) alkyl, -0-C(l-6) alkyl and halogen; and Ri is neopentyl;
R2 is
Figure imgf000011_0004
R3 is phenyl, which is substituted with one or two substituents independently selected from -0-C(l-6) alkyl, -C(0)-NH2 and -C(0)-OH;
R4 and R5 are independently selected from hydrogen and -C(l-6) alkyl, which alkyl is not substituted or substituted with a substituent selected from hydroxyl and tetrahydropyranyl; and pharmaceutically acceptable salts thereof. In another embodiment there are provided the compounds of the formula (II) as defined above, wherein
Figure imgf000012_0001
and R6 is selected from hydrogen, -C(l-6) alkyl, -0-C(l-6) alkyl and halogen.
[0014] Especially preferred are compounds of the formulas
chiral 4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo- l\2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-
3-methoxybenzamide,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide,
rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide,
rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-l',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-b]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-l',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid, rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'-dioxo- l\2\7,7a-tetra ydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)- 3-methoxybenzoic acid,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'-dioxo- l\2\7,7a-tetra ydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)- 3 -methoxybenzamide,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetra ydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-2- methoxybenzamide,
rac-4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'-dioxo- 1^2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)- 3-methoxybenzamide,
chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3-methyl-5-neopentyl-l,2'- dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-
2(lH,3H,5H)-yl)-3-methoxybenzamide,
chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3-ethyl-5-neopentyl-l,2'- dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]- 2(lH,3H,5H)-yl)-3-methoxybenzamide,
chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3-(hydroxymethyl)-5- neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2- c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide;
chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-3-(2-
(tetrahydro-2H-pyran-4-yl)ethyl)- l',2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2-c]imidazole-6,3'- pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide;
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid and
rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-b]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid. [0015] In the specification where indicated the various groups may be substituted by 1-5 or, preferably, 1-3 substituents independently selected from the group consisting of lower alkyl, lower-alkenyl, lower- alkynyl, dioxo-lower-alkylene (forming e.g. a benzodioxyl group), halogen, hydroxy, CN, CF3, NH2, N(H, lower-alkyl), N(lower-alkyl)2, aminocarbonyl, carboxy, N02, lower-alkoxy, thio-lower-alkoxy, lower-alkylsufonyl, aminosulfonyl, lower-alkylcarbonyl, lower-alkylcarbonyloxy, lower-alkoxycarbonyl, lower-alkyl-carbonyl-NH, fluoro-lower-alkyl, fluoro-lower-alkoxy, lower-alkoxy-carbonyl-lower-alkoxy, carboxy-lower-alkoxy, carbamoyl- lower-alkoxy, hydroxy-lower-alkoxy, NH2-lower-alkoxy, N(H, lower-alkyl)-lower-alkoxy, N(lower-alkyl)2-lower-alkoxy, lower-alkyl- 1-oxiranyl-lower-alkoxy-lower-alkyl, 2-oxo- pyrrolidin-l-yl, (l,l-dioxo)-2-isothiazolidine, 3-lower-alkyl sulfinyl, a substituted or
unsubstituted heterocyclic ring, a substituted or unsubstituted aryl ring, a substituted or unsubstituted heteroaryl ring, trifluoro-lower-alkylsulfonylamino-aryl, lower-alkyl
sulfonylaminocarbonyl, lower-alkyl sulfonylaminocarbonyl-aryl, hydroxycarbamoyl-phenyl, benzyloxy-lower-alkoxy, mono- or di-lower alkyl substituted amino-sulfonyl and lower-alkyl which can optionally be substituted with halogen, hydroxy, NH2, N(H, lower-alkyl) or N(lower- alkyl)2.. Preferred substituents for the cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycle rings are halogen, lower alkoxy, lower alkyl, hydroxycarbonyl, carboxy, carboxy lower alkoxy, oxo and CN. Preferred substituents for alkyl are alkoxy and N(lower alkyl)2.
Terms & Definitions
[0016] "Substituted," as in substituted alkyl, means that the substitution can occur at one or more positions and, unless otherwise indicated, that the substituents at each substitution site are independently selected from the specified options. The term "optionally substituted" refers to the fact that one or more hydrogen atoms of a chemical group (with one or more hydrogen atoms) can be, but does not necessarily have to be, substituted with another substituent. In the specification where indicated the various groups may be substituted by preferably, 1-3
substituents independently selected from the group consisting of H, carboxyl, amido, hydroxyl, alkoxy, substituted alkoxy, sulfide, sulfone, sulfonamide, sulfoxide, halogen, nitro, amino, substituted amino, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl, substituted lower cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle;
[0017] The term "alkyl" refers to straight- or branched-chain saturated hydrocarbon groups having from 1 to about 20 carbon atoms, including groups having from 1 to 7 carbon atoms. In certain embodiments, alkyl substituents may be lower alkyl substituents. The term "lower alkyl" refers to alkyl groups having from 1 to 6 carbon atoms, and in certain embodiments from 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl,
1- propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl.
[0018] As used herein, "cycloalkyl" is intended to refer to any stable monocyclic or polycyclic system which consists of carbon atoms only, any ring of which being saturated, and the term "cycloalkenyl" is intended to refer to any stable monocyclic or polycyclic system which consists of carbon atoms only, with at least one ring thereof being partially unsaturated. Examples of cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, bicycloalkyls, including bicyclooctanes such as
[2.2.2]bicyclooctane or [3.3.0]bicyclooctane, bicyclononanes such as [4.3.0]bicyclononane, and bicyclodecanes such as [4.4.0]bicyclodecane (decalin), or spiro compounds. Examples of cycloalkenyls include, but are not limited to, cyclopentenyl or cyclohexenyl.
The term "alkenyl" as used herein means an unsaturated straight-chain or branched aliphatic hydrocarbon group containing one double bond and having 2 to 6, preferably 2 to 4 carbon atoms.
[0019] Examples of such "alkenyl group" are vinyl, ethenyl, allyl, isopropenyl, 1-propenyl, 2- methyl-l-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-l-butenyl, 3-methyl-2-butenyl, 1- pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3- hexenyl, 4-hexenyl and 5-hexenyl.
[0020] The term "alkynyl" as used herein means an unsaturated straight-chain or branched aliphatic hydrocarbon group containing one triple bond and having 2 to 6, preferably 2 to 4 carbon atoms. Examples of such "alkynyl group" are ethynyl, 1-propynyl, 2-propynyl, 1-butynyl,
2- butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3- hexynyl, 4-hexynyl and 5-hexynyl.
[0021] The term "halogen" as used in the definitions means fluorine, chlorine, bromine, or iodine, preferably fluorine and chlorine.
[0022] "Aryl" means a monovalent, monocyclic or bicyclic, aromatic carbocyclic
hydrocarbon radical, preferably a 6-10 member aromatic ring system. Preferred aryl groups include, but are not limited to, phenyl, naphthyl, tolyl, and xylyl. [0023] "Heteroaryl" means an aromatic heterocyclic ring system containing up to two rings. Preferred heteroaryl groups include, but are not limited to, thienyl, furyl, indolyl, pyrrolyl, pyridinyl, pyrazinyl, oxazolyl, thiaxolyl, quinolinyl, pyrimidinyl, imidazole and tetrazolyl.
In the case of aryl or heteroaryl which are bicyclic it should be understood that one ring may be aryl while the other is heteroaryl and both being substituted or unsubstituted.
[0024] "Heterocycle" means a substituted or unsubstituted 5 to 8 membered, mono- or bicyclic, non-aromatic hydrocarbon, wherein 1 to 3 carbon atoms are replaced by a hetero atom selected from nitrogen, oxygen or sulfur atom. Examples include pyrrolidin-2-yl; pyrrolidin-3-yl;
piperidinyl; morpholin-4-yl and the like.
"Hetero atom" means an atom selected from N, O and S.
[0025] "Alkoxy, alkoxyl or lower alkoxy" refers to any of the above lower alkyl groups attached to an oxygen atom. Typical lower alkoxy groups include methoxy, ethoxy, isopropoxy or propoxy, butyloxy and the like. Further included within the meaning of alkoxy are multiple alkoxy side chains, e.g. ethoxy ethoxy, methoxy ethoxy, methoxy ethoxy ethoxy and the like and substituted
alkoxy side chains, e.g., dimethylamino ethoxy, diethylamino ethoxy, dimethoxy-phosphoryl methoxy and the like.
[0026] "Pharmaceutically acceptable," such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered. [0027] "Pharmaceutically acceptable salt" refers to conventional acid-addition salts or base- addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, trifluoro acetic acid and the like. Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide. Chemical modification of a pharmaceutical compound (i.e. drug) into a salt is a technique well known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See, e.g., Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196 and 1456- 1457. [0028] The compounds of formula I and II as well as their salts that have at least one
asymmetric carbon atom may be present as racemic mixtures or different stereoisomers. The various isomers can be isolated by known separation methods, e.g., chromatography.
[0029] Compounds disclosed herein and covered by formula I and II above may exhibit tautomerism or structural isomerism. It is intended that the invention encompasses any tautomeric or structural isomeric form of these compounds, or mixtures of such forms, and is not limited to any one tautomeric or structural isomeric form depicted in the formulas above.
[0030] The compounds of the present invention are useful in the treatment or control of cell proliferative disorders, in particular oncological disorders. These compounds and formulations containing said compounds may be particularly useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors.
[0031] A therapeutically effective amount of a compound in accordance with this invention means an amount of compound that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is within the skill in the art.
[0032] The therapeutically effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art.
Such dosage will be adjusted to the individual requirements in each particular case including the specific compound(s) being administered, the route of administration, the condition being treated, as well as the patient being treated. In general, in the case of oral or parenteral administration to adult humans weighing approximately 70 Kg, a daily dosage of about 10 mg to about 10,000 mg, preferably from about 200 mg to about 1,000 mg, should be appropriate, although the upper limit may be exceeded when indicated. The daily dosage can be administered as a single dose or in divided doses, or for parenteral administration; it may be given as continuous infusion.
[0033] Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, as well as the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of a formula I compound which produces a therapeutic effect.
Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
[0034] Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
[0035] Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, sachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non- aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.
[0036] "Effective amount" means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
[0037] "IC50" refers to the concentration of a particular compound required to inhibit 50% of a specific measured activity. IC50 can be measured, inter alia, as is described subsequently.
Synthetic Methods
[0038] The present invention provides novel methods for the synthesis of the substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'-pyrrolo[l,2-c]imidazole]- ,2(lH,5'H)-dione derivatives of formula I or II. Compounds of this invention can be synthesized according to the following general schemes. The detailed processes for synthesizing these compounds are provided in the examples.
[0039] An intermediate III can be made from a base-catalyzed condensation reaction of appropriately selected substituted 4- or 5- or 6- or 7-aza-2-oxindole I and appropriate substituted aldehyde II in methanol (Scheme 1). The choice of bases includes but is not limited to pyrrolidine or piperidine. The reaction generates III as a mixture of Z- and E-isomers with E- isomer as the major product.
Scheme 1
Figure imgf000019_0001
m = 0-3
Reagents and conditions: pyrrolidine or piperidine, MeOH , 50 °C, 3 h
[0040] Similarly, intermediates V or VII can be made from an acid-catalyzed condensation reaction of appropriately selected substituted 5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one IV or 4,6-dihydro-thieno[3,2-b]pyrrol-5-one VI and aldehyde II in hydrochloric and acetic aicd (M. Cheung et al, Tetrahedron Lett. 2001, 42, 999) (Scheme 2).
Scheme 2
Figure imgf000020_0001
IV
Figure imgf000020_0002
VI VII
m is 0-2
Reagents and conditions: acetic acid and concentrated HCI, room temperature, 18 h
[0041] Preparation of starting material Via is described in Scheme 3 to exemplify the synthesis of intermediate VI in Scheme 2. 2,5-Dichlorothiophene can be treated with sodium nitrate in concentrated sulfuric acid to give 2,5-dichlorothiphene-3-nitrothiophene. Nucleophilic substitution of 5-chloro group with tert-butyl ethyl malonate mono-sodium salt and treatment with trifluoroacetic acid lead to methyl 2-(5-chloro-3-nitrothiophen-2-yl)acetate
(WO2008132139). Reduction of nitro group with zinc and ammonium chloride and cyclizing reaction to form amide promoted by trimethylaluminum afford intermediate Via (S. Hu, et al, J. Heterocyclic. Chem. 2005, 42, 661).
Scheme 3
Figure imgf000021_0001
Via
Reagents and conditions:
a) NaN03, cone, sulfuric acid, 0 °C, 3 min;
b) tert-butyl ethyl malonate, NaH, DMSO, 60 °C, 3 h;
c) TFA, CH2CI2, room temperature, 18 h;
d) Zinc, NH4CI, MeOH/H20, room temperature, 1 h;
e) AIMe3, toluene, 0-10 °C, 0.5 h;
[0042] Racemic synthesis of compounds XI and XII can be achieved as outlined in Scheme 4. Amine R3NH2 can be reacted with N-protected glycine like N-Boc glycine by using a coupling reagent like EDCI or HATU to give intermediate VIII. Intermediate VIII can be treated with trifluoroacetic acid or HC1 at room temperature to remove protective Boc group and give intermediate IX. Appropriately selected aldehyde RiCHO can react with IX to give the imine X. The cylcoaddition reaction between intermediates X and intermediate III or V or VII mediated by LiOH or LiCl/DABCO gives a racemic and diastereomeric mixture of compounds XI together with other isomers. Compounds XI can be purified by flash chromatography followed by chiral separation by chiral Super Fluid Chromatography (SFC) or chiral HPLC to give oprically pure or enriched chiral compounds XII. Scheme 4
Figure imgf000022_0001
or V or VII XI XII
Reagents and conditions:
a. EDCI, or HATU/iPr2NEt, CH2CI2 , rt, 4 h;
b. TFA or HCI, CH2CI2, rt, 1 h;
c. NEt3, tert-butyl methyl ether, rt, 18 h
d. LiOH, 40 °C, 24 h;
e. Flash chromatography and Chiral SFC separation
[0043] Similarly, compounds XI and XII can be prepared as outlined in Scheme 5.
Intermediate III or V or VII can be protected with Boc group to give intermediate XIII. The cylcoaddition reaction between intermediates X and XIII mediated by LiOH or LiCl/DABCO follow by reaction to remove Boc group by trifluroacetic aicd give compounds XI. Compounds XI can be subsequently separated into oprically pure or enriched chiral compounds XII. Scheme 5
Figure imgf000023_0001
Reagents and conditions:
a. Boc20, DAMP, CH2CI2 , rt, 3 h;
b. LiOH, 40 °C, 24 h;
c. TFA, CH2CI2, rt, 1 h;
d. Flash chromatography and Chiral SFC separation
[0044] Alternative synthesis of compounds Xlla can be achieved. As illustrated in Scheme 6, selected aldehyde RiCHO can be reacted with glycine tert-butyl ester to generate imine XIV. The racemic mixture of intermediate XV and XV can be made from intermediates XIV and VII by LiOH mediated cyclization reaction. The mixture of XVI and XVI' can be subsequently converted to a racemic mixture of acid XVII and XVII' by using trifluoro acetic acid. Amide formation with various amine NHR3P by using diphenylphosphinic chloride as the coupling reagent can lead to the racemic mixture of compounds Xlla and Xlla'. Finally chiral separation by chiral Super Fluid Chromatography (SFC) or chiral HPLC gives optically pure or enriched chiral compounds Xlla.
Figure imgf000024_0001
Figure imgf000024_0002
Reagents and conditions:
a. CH2CI2 , rt, 4 h;
b. LiOH, 40 °C, 24 h;
c. TFA or HCI, CH2CI2, rt, 18 h;
d. R3NH2, iPr2NEt, Ph2P(=0)CI, CH2CI2, rt, 18 h;
e. Chiral SFC separation
[0045] Synthesis of compounds XVIII and XIX in formula I or II can be achieved by the reaction of intermediates XI or XII with a vaiiety of aldehydes or ketones XVII in acidic condition (preferably acetic acid) followed by aqueous basic workup (Scheme 7).
Figure imgf000025_0001
Reagents and conditions:
(a) HOAc, 40-120 °C, CH2CI2, (b) aq. NaOH, EtOH, 50 °C
Examples
[0046] The compounds of the present invention may be synthesized according to novel techniques. The following examples and references are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims.
Example 1
Preparation of chiral 4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'- dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-
2(lH,3H,5H)-yl)-3-methoxybenzamide
Figure imgf000026_0001
M.W. 626.52 C31H30CI2FN5C
[0047] Step a: To a solution of chiral (2S,3R,4S,5R)-N-(4-carbamoyl-2-methoxyphenyl)-6'- chloro-4-(3 -chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- 1 ',2'-dihydrospiro[pyrrolidine-3 ,3 '- pyrrolo[3,2-c]pyridine]-5-carboxamide (24 mg, 0.039 mmol) and acetic acid (0.4 mL) in dichloromethane (0.4 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (27 mg, 0.02 mL, 0.336 mmol). The reaction mixture was heated under argon at 40 °C overnight. It was then poured into 2 N NaOH (4 mL) and water (5 mL) and extracted with EtOAc (10 mL). The organic layer was washed with water (8 mL) and concentrated to give a crude film, chiral 4- ((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-l'-(hydroxymethyl)-5-neopentyl-l,2'- dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]- 2(lH,3H,5H)-yl)-3-methoxybenzamide (24 mg, 95 yield). [0048] Step b: The above crude chiral 4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide (24 mg, 0.037 mmol) was mixed with EtOH (3 mL) and treated with a solution of 2N NaOH (0.53 mL, 1.06 mmol). The reaction mixture was heated to 50 °C and stirred for 1 hr when LCMS showed the reaction was complete. The reaction mixture was poured into EtOAc (20 mL), washed with water (10 mL) and concentrated. The crude product was purified by flash chromatography (1% to 15% ethanol in dichloromethane) to give chiral 4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)-5-neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'- pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide as a white solid (10.6 mg, 44 % yield). MS (ES+) m/z [(M+H)+]: 626
Example 2
Preparation of rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'- dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]- 2(lH,3 -yl)-3-methoxybenzoic acid
Figure imgf000027_0001
M.W. 607.09, C32H32C1FN405
[0049] Step a: To a solution of methyl rac-4-((2S,3R,4S,5R)-4-(3-chloro-2-fluorophenyl)-6'- methyl-2-neopentyl-2'-oxo- ,2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2-c]pyridine]-5- ylcarboxamido)-3-methoxybenzoate (46 mg, 0.0762 mmol) and acetic acid (0.55 mL) in dichloromethane (0.6 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (33 mg, 0.03 mL, 0.403 mmol). The reaction mixture was heated under argon at 40 °C overnight. It was then poured into 2 N NaOH (4.5 mL) and water (5 mL) and extracted with EtOAc (20 mL). The organic layer was washed with water (10 mL) and concentrated to give crude methyl rac-4-((2S,3R,4S,5R)-4-(3-chloro-2-fluorophenyl)-6'-methyl-2-neopentyl-2'-oxo-l',2'- dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2-c]pyridine]-5-ylcarboxamido)-3-methoxybenzoate (61 mg) which was used without further purification.
[0050] Step b: The above crude methyl rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-l'- (hydroxymethyl)-6'-methyl-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (61 mg, 0.0762 mmol) was mixed with EtOH (6 mL) and treated with a solution of 2N NaOH (1.0 mL, 2.00 mmol). The reaction mixture was heated to 50 °C and stirred for 1 hr when LCMS showed the reaction was complete. The reaction mixture was neutralized with IN HCl (2 mL to pH 6) and diluted with EtOAc (25 mL), washed with H20 (10 mL), concentrated and lyophilized from MeCN and water to give rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5- neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2- c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoic acid (36 mg, 79 %). MS (ES+) m/z [(M+H)+]: 607
Example 3
Preparation of rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'- dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]- 2(lH,3H,5H)-yl)-3-methoxybenzamide(A)
and
[0051] rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo- 1^2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-
3 -methoxybenzamide(B )
Figure imgf000028_0001
M.W.606.10, C32H33C1FN504
[0052] A mixture of rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5- neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2- c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoic acid (30 mg, 0.049 mmol, Example 2) and N,N -carbonyldiimidazole (Aldrich, 36 mg, 0.226 mmol) in THF (4 mL) was stirred at rt overnight. Ammonium hydroxide (234 mg, 0.26 mL, 6.68 mmol) was added and the mixture was stirred for 20 min. The mixture was partitioned between EtOAc (75 mL) and water (10 mL), washed with sat. NaHC03 (10 mL), water (10 mL) then sat. NH4C1 (10 mL). The organic layer was dried over Na2S04 and concentrated in vacuo onto silica gel. The crude material was purified by flash chromatography (2% to 12% EtOH in EtOAc) to give rac-4-((3'R,5S,7S,7aR)- 7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (A)(9 mg, 29 %) as a white solid, MS (ES+) m/z [(M+H)+]: 605, and rac-4- ((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (B)(17 mg, 56%) as a white solid, MS (ES+) m/z [(M+H)+]: 606. Example 4
Preparation of rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo- l\2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-b]pyridine]-2(lH,3H,5H)-yl)-
3-methoxybenzoic acid
Figure imgf000029_0001
M.W. 593.06 C3iH3oClFN405
[0053] Step a: To a solution of methyl rac-4-((2S,3S,4S,5R)-4-(3-chloro-2-fluorophenyl)-2- neopentyl-2'-oxo-1^2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2-b]pyridine]-5-ylcarboxamido)- 3-methoxybenzoate (50 mg, 0.084 mmol) and acetic acid (0.7 mL) in dichloromethane (0.7 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (44 mg, 0.04 mL, 0.53 mmol). The reaction mixture was heated under argon at 40 °C overnight. It was then poured into 2 N NaOH (4.5 mL) and extracted with EtOAc (2x20 mL). The organic layer was washed with water (10 mL) and concentrated to give crude methyl rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-b]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (52 mg) which was used without further purification. [0054] Step b: The above crude crude methyl rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-b]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (52 mg, 0.082 mmol) was dissolved in MeOH (4 mL) and treated with a solution of 2N NaOH (0.7 mL, 1.40 mmol). The reaction mixture was heated to 50 °C and stirred for 5 hr when LCMS showed the reaction was complete. The reaction mixture was neutralized with IN HCl (1.4 mL to pH 6) and diluted with EtOAc (75 mL), washed with H20 (3x15 mL), concentrated. The crude material was absorbed on silica gel and purified by flash chromatography (silica gel, 4 g, 1% to 20% ethanol in CH2C12) to give rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl- l,2'-dioxo-l\2^7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-b]pyridine]- 2(lH,3H,5H)-yl)-3-methoxybenzoic acid (8.8 mg, 18 % yield). MS (ES+) m/z [(M+H)+]: 593.
Example 5
Preparation of rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo- l\2^7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-
3-methoxybenzoic acid
Figure imgf000030_0001
M.W. 593.06 C3iH3oClFN405
[0055] Step a: To a solution of methyl rac-4-((2S,3R,4S,5R)-4-(3-chloro-2-fluorophenyl)-2- neopentyl-2'-oxo-1^2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2-c]pyridine]-5-ylcarboxamido)- 3-methoxybenzoate (40 mg, 0.067 mmol) and acetic acid (0.5 mL) in dichloromethane (0.5 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (27 mg, 0.025 mL, 0.34 mmol). The reaction mixture was heated under argon at 40 °C overnight. It was then poured into 2 N NaOH (4.5 mL) and extracted with EtOAc (2x20 mL). The organic layer was washed with water (10 mL) and concentrated to give crude methyl rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- l',2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (58 mg) which was used without further purification. [0056] Step b: The above crude crude methyl rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (58 mg, 0.067 mmol) was dissolved in EtOH (5 mL) and treated with a solution of 2N NaOH (0.9 mL, 1.80 mmol). The reaction mixture was heated to 50 °C and stirred for 2 hr when LCMS showed the reaction was complete. The reaction mixture was neutralized with IN HC1 and diluted with EtOAc (20 mL), washed with H20 (2x10 mL), concentrated and lyophilized to give rac-4- ((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid (31 mg, 77%). MS (ES+) m/z [(M+H)+]: 593.
Example 6
Preparation of rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'- dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]- 2(lH,3H,5H)-yl)-3-methoxybenzoic acid
Figure imgf000031_0001
M.W. 623.09, C32H32C1FN406
[0057] Step a: To a solution of methyl 4-((2S,3R,4S,5R)-4-(3-chloro-2-fluorophenyl)-6'- methoxy-2-neopentyl-2'-oxo-1^2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2-c]pyridine]-5- ylcarboxamido)-3-methoxybenzoate (45 mg, 0.072 mmol) and acetic acid (0.52 mL) in dichloromethane (0.5 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (32 mg, 0.030 mL, 0.40 mmol). The reaction mixture was heated under argon at 40 °C overnight. It was then poured into 2 N NaOH (4.3 mL) and extracted with EtOAc (2x20 mL). The organic layer was washed with water (10 mL) and concentrated to give crude methyl 4-((3'R,5S,7S,7aR)- 7-(3-chloro-2-fluorophenyl)- 1 '-(hydroxymethyl)-6'-methoxy-5-neopentyl- 1 ,2'-dioxo- 1 ',2' ,7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoate (86 mg) which was used without further purification.
[0058] Step b: The above crude methyl 4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-l'- (hydroxymethyl)-6'-methoxy-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (86 mg, 0.072 mmol) was dissolved in EtOH (5 mL) and treated with a solution of 2N NaOH (0.95 mL, 1.90 mmol). The reaction mixture was heated to 50 °C and stirred for 2 hr when LCMS showed the reaction was complete. The reaction mixture was neutralized with IN HC1 and diluted with EtOAc (20 mL), washed with H20 (2x10 mL), concentrated and lyophilized to give rac-4- ((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid (19 mg, 42%). MS (ES+) m/z [(M+H)+]: 623.
Example 7
Preparation of rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'- dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-
2(lH, -yl)-3-methoxybenzamide
Figure imgf000032_0001
M.W. 622.10, C32H33CIFN5O5
[0059] A mixture of rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5- neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2- c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoic acid (14 mg, 0.022 mmol, Example 6) and N,N -carbonyldiimidazole (Aldrich, 17 mg, 0.109 mmol) in THF (3 mL) was stirred at rt overnight. Ammonium hydroxide (108 mg, 0.12 mL, 0.912 mmol) was added and the mixture was stirred for 20 min. The mixture was partitioned between EtOAc (75 mL) and water (10 mL), washed with sat. NaHC03 (10 mL), water (10 mL) then sat. NH4C1 (10 mL). The organic layer was dried over Na2S04 and concentrated in vacuo onto silica gel. The crude material was purified by flash chromatography (2% to 12% EtOH in EtOAc) to give rac-4-((3'R,5S,7S,7aR)- 7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'-dioxo- ,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (9.7 mg, 68 %) as a white solid, MS (ES+) m z [(M+H)+]: 622
Example 8
Preparation of rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo- 1^2^7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-
2-methoxybenzamide
Figure imgf000033_0001
M.W. 592.08, C3IH3IC1FN504
[0060] Step a: To a solution of rac-(2S,3R,4S,5R)-N-(4-carbamoyl-3-methoxyphenyl)-4-(3- chloro-2-fluorophenyl)-2-neopentyl-2'-oxo-r,2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2- c]pyridine]-5-carboxamide (20.7 mg, 0.035 mmol) and acetic acid (0.3 mL) in dichloromethane (0.5 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (22 mg, 0.020 mL, 0.27 mmol). The reaction mixture was heated under argon at 40 °C overnight. It was then poured into 2 N NaOH (4.5 mL) and extracted with EtOAc (2x20 mL). The organic layer was washed with water (10 mL) and concentrated to give crude rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-2-methoxybenzamide (23.9 mg) which was used without further purification.
[0061] Step b: The above crude rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-l'- (hydroxymethyl)-5-neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'- pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-2-methoxybenzamide (23.9 mg, 0.035 mmol) was dissolved in EtOH (5 mL) and treated with a solution of 2N NaOH (0.48 mL, 0.96 mmol). The reaction mixture was heated to 50 °C and stirred for 2 hr when LCMS showed the reaction was complete. The reaction mixture was neutralized with IN HC1 and diluted with EtOAc (20 mL), washed with H20 (2x10 mL), concentrated and lyophilized to give rac-4-((3'R,5S,7S,7aR)-7-(3- chloro-2-fluorophenyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-2-methoxybenzamide (5.3 mg, 25%). MS (ES+) m/z [(M+H)+]: 592.
Example 9
Preparation of rac-4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'- dioxo-l\2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]- 2(lH,3H,5H)-yl)-3-methoxybenzoic acid
Figure imgf000034_0001
M.W. 627.50, C3iH29Cl2FN405
[0062] Step a: To a solution of rac-methyl 4-((2S,3R,4S,5R)-6'-chloro-4-(3-chloro-2- fluorophenyl)-2-neopentyl-2'-oxo-l\2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[2,3-b]pyridine]-5- ylcarboxamido)-3-methoxybenzoate (45 mg, 0.071 mmol) and acetic acid (0.52 mL) in dichloromethane (0.5 mL), was added formaldehyde (contains 10-15% methanol as inhibitor) (32 mg, 0.030 mL, 0.40 mmol). The reaction mixture was heated under argon at 40 °C overnight. It was then poured into 2 N NaOH (4.3 mL) and extracted with EtOAc (2x20 mL). The organic layer was washed with water (10 mL) and concentrated to give crude rac-methyl 4- ((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-l'-(hydroxymethyl)-5-neopentyl-l,2'- dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]-
2(lH,3H,5H)-yl)-3-methoxybenzoate (48 mg) which was used without further purification. [0063] Step b: The above crude rac-methyl 4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)- 1 '-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2- c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoate (48 mg, 0.071 mmol) was dissolved in EtOH (5 mL) and treated with a solution of 2N NaOH (0.96 mL, 1.92 mmol). The reaction mixture was heated to 50 °C and stirred for 2 hr when LCMS showed the reaction was complete. The reaction mixture was neutralized with IN HC1 and diluted with EtOAc (20 mL), washed with H20 (2x10 mL), concentrated and lyophilized to give rac-4- ((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid (38.7 mg, 86.3 %). MS (ES+) m/z [(M+H)+]: 627.
Example 10
Preparation of rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'- dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]- 2(lH,3H,5H)-yl)-3-methoxybenzamide
Figure imgf000035_0001
M.W. 626.52, C3iH30Cl2FN5O4
[0064] A mixture of rac-4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5- neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[2,3- b]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzoic acid (32 mg, 0.052 mmol, Example 9) and N,N -carbonyldiimidazole (Aldrich, 37 mg, 0.232 mmol) in THF (7 mL) was stirred at rt overnight. Ammonium hydroxide (251 mg, 0.28 mL, 2.13 mmol) was added and the mixture was stirred for 20 min. The mixture was partitioned between EtOAc (75 mL) and water (10 mL), washed with sat. NaHC03 (10 mL), water (10 mL) then sat. NH4C1 (10 mL). The organic layer was dried over Na2S04 and concentrated in vacuo onto silica gel. The crude material was purified by flash chromatography (2% to 12% EtOH in EtOAc) to give rac-4-((3'R,5S,7S,7aR)- 6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo- ,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (18.8 mg, 57.8 %) as a white solid, MS (ES+) m/z [(M+H)+]: 626
Example 11
Preparation of chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3-methyl-5- neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2- c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide
Figure imgf000036_0001
M.W. 640.55, C32H32Cl2FN504
[0065] Step a: To a solution of chiral (2S,3R,4S,5R)-N-(4-carbamoyl-2-methoxyphenyl)-6'- chloro-4-(3-chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- ,2'-dihydrospiro[pyrrolidine-3,3'- pyrrolo[3,2-c]pyridine]-5-carboxamide (21 mg, 0.034 μιηοΐ mmol) and acetic acid (0.5 mL) in dichloromethane (0.5 mL), was added acetaldehyde (27.5 mg, 0.035 mL, 0.624 mmol). The reaction mixture was heated under argon at 40 °C overnight. It was then poured into 2 N NaOH (4 mL) and water (5 mL) and extracted with EtOAc (10 mL). The organic layer was washed with water (8 mL) and concentrated to give crude chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro- 2-fluorophenyl)-l'-(l-hydroxyethyl)-3-methyl-5-neopentyl-l,2'-dioxo- ,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (88 mg) which was used without further purification.
[0066] Step b: The above crude chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)- 1 '-( 1 -hydroxyethyl)-3-methyl-5-neopentyl- 1 ,2'-dioxo- 1 ',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (87 mg, 0.034 mmol) was mixed with EtOH (3 mL) and treated with a solution of 2N NaOH (0.46 mL, 0.92 mmol). The reaction mixture was heated to 50 °C and stirred for 1 hr when LCMS showed the reaction was complete. The reaction mixture was poured into EtOAc (20 mL), washed with water (10 mL) and concentrated. The crude product was purified by flash chromatography (1% to 15% ethanol in dichloromethane) to give chiral 4- ((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3-methyl-5-neopentyl-l,2'-dioxo- l\2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)- 3-methoxybenzamide as a white solid (12.5 mg, 56 %). MS (ES+) m z [(M+H)+]: 640
Example 12
Preparation of chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3-ethyl-5- neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2- c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide
Figure imgf000037_0001
M.W. 654.57, C33H34C12FN504
[0067] Step a: To a solution of chiral (2S,3R,4S,5R)-N-(4-carbamoyl-2-methoxyphenyl)-6'- chloro-4-(3-chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- ,2'-dihydrospiro[pyrrolidine-3,3'- pyrrolo[3,2-c]pyridine]-5-carboxamide (20 mg, 0.033 μιηοΐ mmol) and acetic acid (0.5 mL) in dichloromethane (0.5 mL), was added propionaldehyde (40 mg, 0.67 mmol). The reaction mixture was heated under argon at 40 °C overnight. It was then poured into 2 N NaOH (4 mL) and water (5 mL) and extracted with EtOAc (10 mL). The organic layer was washed with water (8 mL) and concentrated to give crude 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)-3 -ethyl- 1 '-( 1 -hydroxypropyl)-5-neopentyl- 1 ,2'-dioxo- 1 ',2' ,7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (44.5 mg) which was used without further purification.
[0068] Step b: The above crude chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)-3 -ethyl- 1 '-( 1 -hydroxypropyl)-5-neopentyl- 1 ,2'-dioxo- 1 ',2' ,7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (44.5 mg, 0.033 mmol) was mixed with EtOH (3 mL) and treated with a solution of 2N NaOH (0.46 mL, 0.92 mmol). The reaction mixture was heated to 50 °C and stirred for 1 hr when LCMS showed the reaction was complete. The reaction mixture was poured into EtOAc (20 mL), washed with water (10 mL) and concentrated. The crude product was purified by flash chromatography (1% to 15% ethanol in dichloromethane) to give chiral 4- ((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3-ethyl-5-neopentyl-l,2'-dioxo- l\2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'^yrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)- 3-methoxybenzamide as a white solid ((11.2 mg, 51 %). MS (ES+) m z [(M+H)+]: 654
Example 13
Preparation of chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3- (hydroxymethyl)-5-neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'- pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide
Figure imgf000038_0001
M.W. 656.55, C32H32CI2FN5O5
[0069] Step a: To a solution of chiral (2S,3R,4S,5R)-N-(4-carbamoyl-2-methoxyphenyl)-6'- chloro-4-(3-chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- ,2'-dihydrospiro[pyrrolidine-3,3'- pyrrolo[3,2-c]pyridine]-5-carboxamide (29.7 mg, 0.048 mmol) and acetic acid (1 mL) in dichloromethane (1 mL) in a microwave vial, was added Tert-butyldimethylsilyloxy
acetaldehyde (183 mg, 0.2 mL, 0.945 mmol). The reaction mixture was heated under argon at 120 °C in the microwave for 30 min. It was then poured into 2 N NaOH (4 mL) and water (5 mL) and extracted with EtOAc (10 mL). The organic layer was washed with water (8 mL) and concentrated to give crude 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-l'-(l,2- dihydroxyethyl)-3-(hydroxymethyl)-5-neopentyl-l,2'-dioxo-l',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (162 mg) which was used without further purification. [0070] Step b: The above crude chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)- 1 '-( 1 ,2-dihydroxyethyl)-3-(hydroxymethyl)-5-neopentyl- 1 ,2'-dioxo- 1 ',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide (162 mg) was mixed with EtOH (3 mL) and treated with a solution of 2N NaOH (0.65 mL, 1.3 mmol). The reaction mixture was heated to 50 °C and stirred for 1 hr when LCMS showed the reaction was complete. The reaction mixture was poured into EtOAc (20 mL), washed with water (10 mL) and concentrated. The crude product was purified by flash
chromatography (1% to 15% ethanol in dichloromethane) to give chiral 4-((3S,3'R,5S,7S,7aR)- 6'-chloro-7-(3-chloro-2-fluorophenyl)-3-(hydroxymethyl)-5-neopentyl-l,2'-dioxo- ,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide as a white solid (5.9 mg, 18.6 %). MS (ES+) m/z [(M+H)+]: 656
Example 14
Preparation of chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl- l,2'-dioxo-3-(2-(tetrahydro-2H-pyran-4-yl)ethyl)- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2- c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide
Figure imgf000039_0001
M.W. 738.69, C38¾2Cl2FN505
[0071] Step a: To a solution of chiral (2S,3R,4S,5R)-N-(4-carbamoyl-2-methoxyphenyl)-6'- chloro-4-(3-chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- ,2'-dihydrospiro[pyrrolidine-3,3'- pyrrolo[3,2-c]pyridine]-5-carboxamide ((21 mg, 0.034 mmol) and acetic acid (1 mL) in dichloromethane (1 mL) in a microwave vial, was added 3-(TETRAHYDRO-2H-PYRAN-4- YL)PROPANAL (24 mg, 0.169 mmol, Biofine Product List). The reaction mixture was heated under argon at 120 °C in the microwave for 1 h. It was then poured into 2 N NaOH (4 mL) and water (5 mL) and extracted with EtOAc (10 mL). The organic layer was washed with water (8 mL) and concentrated to give crude 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)-l'-(l-hydroxy-3-(tetrahydro-2H-pyran-4-yl)propyl)-5-neopentyl-l,2'-dioxo-3-(2- (tetrahydro-2H-pyran-4-yl)ethyl)- 1 ',2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2-c]imidazole-6,3'- pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide (33.1 mg) which was used without further purification. [0072] Step b: The above crude chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2- fluorophenyl)-l'-(l-hydroxy-3-(tetrahydro-2H-pyran-4-yl)propyl)-5-neopentyl-l,2'-dioxo-3-(2- (tetrahydro-2H-pyran-4-yl)ethyl)- r,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2-c]imidazole-6,3'- pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide (33.1 mg) was mixed with EtOH (3 mL) and treated with a solution of 2N NaOH (0.47 mL, 0.94 mmol). The reaction mixture was heated to 50 °C and stirred for 1 hr when LCMS showed the reaction was complete. The reaction mixture was poured into EtOAc (20 mL), washed with water (10 mL) and concentrated. The crude product was purified by flash chromatography (1% to 15% ethanol in dichloromethane) to give chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo- 3-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-r,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'- pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide as a white solid (10.1 mg, 39 %). MS (ES+) m/z [(M+H)+]: 738
Example 15
Preparation of rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo- 1^2 7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]-2(lH,3H,5H)-yl)-
3-methoxybenzoic acid
Figure imgf000040_0001
M.W. 593.06 C3iH3oClFN405
[0073] The title compound was prepared in the similar manner as described in Example 4 starting from methyl rac-4-((2S,3R,4S,5R)-4-(3-chloro-2-fluorophenyl)-2-neopentyl-2'-oxo- dihydrospiro[pyrrolidine-3,3'-pyrrolo[2,3-b]pyridine]-5-ylcarboxamido)-3-meth^ and formaldehyde. MS (ES+) m/z [(M+H)+]: 593.
Example 16
Preparation of rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'- dioxo-l\2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-b]pyridine]- 2(lH,3H,5H)-yl)-3-methoxybenzoic acid
Figure imgf000041_0001
M.W. 607.09, C32H32C1FN405
[0074] The title compound was prepared in the similar manner as described in Example 2 starting from rac-4-((2S ,3 S ,4S ,5R)-4-(3 -chloro-2-fluorophenyl)-6'-methyl-2-neopentyl-2'-oxo- 1^2'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[3,2-b]pyridine]-5-ylcarboxamido)-3-methoxybenzoic acid and formaldehyde. MS (ES+) m/z [(M+H)+]: 607
Example 17
In Vitro Activity Assay
[0075] The ability of the compounds to inhibit the interaction between p53 and MDM2 proteins was measured by an HTRF (homogeneous time-resolved fluorescence) assay in which recombinant GST-tagged MDM2 binds to a peptide that resembles the MDM2-interacting region of p53. Binding of GST-MDM2 protein and p53-peptide (biotinylated on its N-terminal end) is registered by the FRET (fluorescence resonance energy transfer) between Europium (Eu)-labeled anti-GST antibody and streptavidin-conjugated Allophycocyanin (APC).
[0076] Test is performed in black flat-bottom 384-well plates (Costar) in a total volume of 40 uL containing:90 nM biotinylate peptide, 160 ng/ml GST-MDM2, 20 nM streptavidin-APC (PerkinElmerWallac), 2 nM Eu-labeled anti- GST- antibody (PerkinElmerWallac), 0.2% bovine serum albumin (BSA), 1 mM dithiothreitol (DTT) and 20 mM Tris-borate saline (TBS) buffer as follows: Add 10 uL of GST-MDM2 (640 ng/ml working solution) in reaction buffer to each well. Add 10 uL diluted compounds (1:5 dilution in reaction buffer) to each well, mix by shaking. Add 20 uL biotinylated p53 peptide (180 nM working solution) in reaction buffer to each well and mix on shaker. Incubate at 37°C for 1 h. Add 20 uL streptavidin-APC and Eu- anti-GST antibody mixture (6 nM Eu-anti-GST and 60 nM streptavidin-APC working solution) in TBS buffer with 0.2% BSA, shake at room temperature for 30 minutes and read using a TRF- capable plate reader at 665 and 615 nm (Victor 5, Perk in ElmerWallac). If not specified, the reagents were purchased from Sigma Chemical Co.
[§§77] Activity data for some of the Example compounds expressed as IC50: bsa: 0.02% are as follows:
Example Number ICsn: bsa: 0.02%
1 0.0068
2 0.1015
3a 0.0899
3b 1.1603
4 0.4845
5 0.7971
6 0.0230
7 0.0150
8 0.1033
9 0.0150
10 0.0193
11 0.0075
12 0.0070
13 0.0096
14 0.0075
15 0.0960
16 0.0218

Claims

Claims
1. A compound of the formula
Figure imgf000043_0001
R6 is selected from the group consisting of H, F, CI, Br, I, CN, N02, ethynyl, cyclopropyl, lower alkyl, vinyl and alkoxy,
R7 is selected from the group consisting of H, F, CI, methyl;
R8 is selected from the group consisting of H, F, CI, methyl;
R9 is selected from the group consisting of H, F, CI, methyl;
wherein in the case of (f) A is a bond;
Ri is independently selected from the group consisting of lower alkyl,
substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl,
substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl;
R2 is selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;
R3 is selected from the group consisting of (CH2)n-R\ (CH2)n-NR'R", (CH2)n-NR'COR", (CH2)n-NR'S02R", (CH2)n-COOH, (CH2)n-COOR\ (CH2)n-CONR'R", (CH2)n-OR\ (CH2)n-SR\ (CH2)n-SOR\ (CH2)n-S02R', (CH2)n-COR', (CH2)n-S03H, (CH2)n-SONR'R", (CH2)„- S02NR'R", (CH2CH20)m-(CH2)n-R', (CH2CH20)m-(CH2)n-OH, (CH2CH20)m-(CH2)n-OR\ (CH2CH20)m-(CH2)n-NR'R", (CH2CH20)m-(CH2)n-NR'COR", (CH2CH20)m-(CH2)n-NR'S02R", (CH2CH20)m-(CH2)n-COOH, (CH2CH20)m-(CH2)n-COOR' , (CH2CH20)m-(CH2)n-CONR'R", (CH2CH20)m-(CH2)n-S02R', (CH2CH20)m-(CH2)n-COR\ (CH2CH20)m-(CH2)n-SONR'R", (CH2CH20)m-(CH2)n-S02NR'R", (CH2)p-(CH2CH20)m-(CH2)n-R' , (CH2)p- (CH2CH20)m- (CH2)n-OH, (CH2)p-(CH2CH20)m-(CH2)n-OR', (CH2)p-(CH2CH20)m-(CH2)n-NR'R", (CH2)P- (CH2CH20)m-(CH2)n-NR'COR", (CH2)p-(CH2CH20)m-(CH2)n-NR'S02R", (CH2)p-(CH2CH20)m- (CH2)n-COOH, (CH2)p-(CH2CH20)m-(CH2)n-COOR' , (CH2)p-(CH2CH20)m-(CH2)n- CONR'R", (CH2)p-(CH2CH20)m-(CH2)n-S02R', (CH2)p-(CH2CH20)m-(CH2)n-COR\ (CH2)p- (CH2CH20)m-(CH2)n-SONR'R", (CH2)p-(CH2CH20)m-(CH2)n-S02NR'R", -COR', -SOR' and S02R'
wherein R' and R' ' are independently selected from H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl, substituted lower cycloalkenyl, aryl, substituted aryl, hetereoaryl, substituted hetereoaryl, hetereocycle or substituted hetereocycle or R and R may independently link to form a cyclic structure selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heteroaryl or substituted or
unsubstituted heterocycle;
m, n and p are independently 0 to 6;
one of R4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R4 and R5 can be combined to form an oxo or thio group;and enantiomers thereof or a pharmaceutically acceptable salt or ester thereof.
. A compound of the formula
Figure imgf000045_0001
R6 is selected from the group consisting of H, F, CI, Br, I,, CN, N02, ethynyl, cyclopropyl, lower alkyl, vinyl and alkoxy;
R7 is selected from the group consisting of H, F, CI, methyl;
R8 is selected from the group consisting of H, F, CI, methyl;
R9 is selected from the group consisting of H, F, CI, methyl;
wherein in the case of (f) A is a bond;
Ri is independently selected from the group consisting of lower alkyl,
substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl;
R2 is selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;
R3 is selected from the group consisting of (CH2)n-R\ (CH2)n-NR'R", (CH2)n-NR'COR", (CH2)n-NR'S02R", (CH2)n-COOH, (CH2)n-COOR\ (CH2)n-CONR'R", (CH2)n-OR\ (CH2)n-SR\ (CH2)n-SOR\ (CH2)n-S02R\ (CH2)n-COR\ (CH2)n-S03H, (CH2)n-SONR'R", (CH2)„- S02NR'R", (CH2CH20)m-(CH2)n-R\ (CH2CH20)m-(CH2)n-OH, (CH2CH20)m-(CH2)n-OR', (CH2CH20)m-(CH2)n-NR'R", (CH2CH20)m-(CH2)n-NR'COR",
(CH2CH20)m-(CH2)n-NR'S02R", (CH2CH20)m-(CH2)n-COOH, (CH2CH20)m-(CH2)n-COOR', (CH2CH20)m-(CH2)n-CONR'R", (CH2CH20)m-(CH2)n-S02R', (CH2CH20)m-(CH2)n-COR\ (CH2CH20)m-(CH2)n-SONR'R", (CH2CH20)m-(CH2)n-S02NR'R", (CH2)p-(CH2CH20)m-(CH2)n- R\ (CH2)p- (CH2CH20)m-(CH2)n-OH, (CH2)p-(CH2CH20)m-(CH2)n-OR', (CH2)p-(CH2CH20)m- (CH2)n-NR'R", (CH2)p-(CH2CH20)m-(CH2)n-NR'COR", (CH2)p-(CH2CH20)m-(CH2)n- NR'S02R", (CH2)p-(CH2CH20)m-(CH2)n-COOH, (CH2)p-(CH2CH20)m-(CH2)n-COOR\ (CH2)P- (CH2CH20)m-(CH2)n-CONR'R", (CH2)p-(CH2CH20)m-(CH2)n-S02R', (CH2)p-(CH2CH20)m- (CH2)n-COR\ (CH2)p-(CH2CH20)m-(CH2)n-SONR'R", (CH2)p-(CH2CH20)m-(CH2)n-S02NR'R", -COR', -SOR' and S02R'
wherein R' and R' ' are independently selected from H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl, substituted lower cycloalkenyl, aryl, substituted aryl, hetereoaryl, substituted hetereoaryl, hetereocycle or substituted hetereocycle or R and R may independently link to form a cyclic structure selected from substituted or
unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycle;
m, n and p are independently 0 to 6;
one of R4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R4 and R5 can be combined to form an oxo or thio group;
and enantiomers thereof or a pharmaceutically acceptable salt or ester thereof.
3. The compound of claim 2 wherein R6 is F, CI or Br.
4. The compound of claim 3 wherein R7 , R8i R9 are all hydrogen.
5. The compound of claim 4 wherein R2 is selected from the group consisting of aryl, substitued with CI or F or Br and heteroaryl optionally substituted with H, F, CI or Br.
6. The compound of claim 5 wherein R is a substituted lower alkyl of the formula
Figure imgf000046_0001
where Rio and Rn are both methyl, or alternatively, Rio and Rn together with the carbon to which they are attached form a ring selected from cyclopropyl, cyclobutyl, cyclopentyl or acyclohexyl ;
Rn is (CH2)q-Ri3, where q is 0, 1 or 2 and
R is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle and substituted heterocycle.
7. The compound of claim 6 wherein R3 is (CH2)n-R\ n is 0 or 1 and R' is aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle or substituted heterocycle.
8. The compound of claim 2 wherein
R6 is selected from F, CI or Br;
R7 , R8, R9 are hydrogen;
R2 is selected from the group consisting of aryl, aryl substitued with CI or F or Br, and heteroaryl optionally substituted with H, F or CI or Br;
Ri is a substituted lower alkyl of the formula
Figure imgf000047_0001
where Rio and Rn are both methyl, or alternatively, Rio and Rn together with the carbon to which they are attached form a ring selected from cyclopropyl, cyclobutyl, cyclopentyl or acyclohexyl;
R12 is (CH2)q-Ri3, where q is 0, 1 or 2;
Ri3 is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle and substituted heterocycle;
R3 is (CH2)„-R' ;
n is 0 or 1 ;
R' is selected from aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle or substituted heterocycle;
one of R4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R4 and R5 can be combined to form an oxo or thio group;
and the enantiomers thereof or a pharmaceutically acceptable salt, or ester thereof.
A compound of the formula
wherein
Figure imgf000048_0001
is selected from the group consisting of
Figure imgf000048_0002
R6 is selected from F, CI or Br;
R7, R8, R9 are hydrogen;
R2 is selected from the group consisting
Figure imgf000048_0003
wherein
Ri4 is F, CI or Br;
Ri5 is H or F;
Figure imgf000049_0001
where Rio and Rn are both methyl, or alternatively, Rio and Rn together with the carbon to which they are attached form a ring selected from cyclopropyl, cyclobutyl, cyclopentyl or acyclohexyl;
Rn is (CH2)q-Ri3, where q is 0, 1 or 2;
Ri3 is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle and substituted heterocycle;
R3 is (CH2)„-R' ;
n is 0 or 1 ;
R' is selected from aryl, substituted aryl, hetereoaryl, substituted heteroaryl, hetereocycle or substituted heterocycle;
one of R4 and R5 is H and the other is selected from the group consisting of H, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl and substituted lower cycloalkenyl or R4 and R5 can be combined to form an oxo or thio group;
or a pharmaceutically acceptable salt thereof. 10. The compound according to cl
Figure imgf000049_0002
II wherein
Figure imgf000050_0001
is selected from the group consisting of
Figure imgf000050_0002
and whereby,
R6 is selected from hydrogen, C(l-6) alkyl, -0-C(l-6) alkyl and halogen; and Ri is neopentyl;
R2 is
Figure imgf000050_0003
R3 is phenyl, which is substituted with one or two substituents independently selected from -0-C(l-6) alkyl, -C(0)-NH2 and -C(0)-OH;
R4 and R5 are independently selected from hydrogen and C(l-6) alkyl, which alkyl is not substituted or substituted with a substituent selected from hydroxyl and tetrahydropyranyl; and pharmaceutically acceptable salts thereof.
11. The compounds according to claim 10, wherein
Figure imgf000050_0004
is
Figure imgf000051_0001
and R6 has the meaning given in claim 10. 12. A compound of claim 1 or 2, selected from the group consisting of
chiral 4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo- l\2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-
3-methoxybenzamide,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide,
rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzamide,
rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-l',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-b]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-l',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'-dioxo- l\2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)- 3 -methoxybenzoic acid,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'-dioxo- l\2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-
3-methoxybenzamide,
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-l',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-2- methoxybenzamide, and rac-4-((3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetra ydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid. 13. A compound of claim 1 or 2, selected from the group consisting of
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methoxy-5-neopentyl-l,2'-dioxo- l\2\7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-
3-methoxybenzamide,
chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3-methyl-5-neopentyl-l,2'- dioxo-1^2^7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]- 2(lH,3H,5H)-yl)-3-methoxybenzamide,
chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3-ethyl-5-neopentyl-l,2'- dioxo-1^2^7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-c]pyridine]- 2(lH,3H,5H)-yl)-3-methoxybenzamide,
chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-3-(hydroxymethyl)- 5-neopentyl-l,2'-dioxo- ,2',7,7a-tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2- c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide;
chiral 4-((3S,3'R,5S,7S,7aR)-6'-chloro-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-3-(2- (tetrahydro-2H-pyran-4-yl)ethyl)- r,2',7,7a-tetrahydrospiro[pyrrolo[ 1 ,2-c]imidazole-6,3'- pyrrolo[3,2-c]pyridine]-2(lH,3H,5H)-yl)-3-methoxybenzamide;
rac-4-((3'R,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-5-neopentyl-l,2'-dioxo-l',2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[2,3-b]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid, and
rac-4-((3'S,5S,7S,7aR)-7-(3-chloro-2-fluorophenyl)-6'-methyl-5-neopentyl-l,2'-dioxo-r,2',7,7a- tetrahydrospiro[pyrrolo[l,2-c]imidazole-6,3'-pyrrolo[3,2-b]pyridine]-2(lH,3H,5H)-yl)-3- methoxybenzoic acid.
14. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 13, together with a pharmaceutically acceptable carrier or excipient.
15. A compound according to any one of claims 1 to 13 for use as a medicament.
16. A compound according to any one of claims 1 to 13 for use as a medicament for the treatment of cancer, in particular solid tumors, more particularly breast, colon, lung and prostate tumors.
17. The use of a compound according to any one of claims 1 to 13 for the manufacture of medicaments for the treatment of cancer, in particular solid tumors, more particularly breast, colon, lung and prostate tumors.
18. The novel compounds, methods and uses substantially as described herein.
PCT/EP2012/053369 2011-03-03 2012-02-28 Substituted heteroaryl 2', 3', 7', 7a' - tetrahydrospiro-[pyrrole-3, 6' - pyrrolo [1, 2-c] imidazole] - 1', 2 (1h, 5'h) -diones as anticancer agents WO2012116989A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448687P 2011-03-03 2011-03-03
US61/448,687 2011-03-03

Publications (1)

Publication Number Publication Date
WO2012116989A1 true WO2012116989A1 (en) 2012-09-07

Family

ID=45787197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/053369 WO2012116989A1 (en) 2011-03-03 2012-02-28 Substituted heteroaryl 2', 3', 7', 7a' - tetrahydrospiro-[pyrrole-3, 6' - pyrrolo [1, 2-c] imidazole] - 1', 2 (1h, 5'h) -diones as anticancer agents

Country Status (2)

Country Link
US (1) US20130053410A1 (en)
WO (1) WO2012116989A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155332A1 (en) * 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2016026937A1 (en) * 2014-08-21 2016-02-25 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2017060431A1 (en) 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036168A2 (en) * 2006-08-30 2008-03-27 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
WO2008132139A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036168A2 (en) * 2006-08-30 2008-03-27 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
WO2008132139A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANSEL ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1995, pages: 196,1456 - 1457
M. CHEUNG ET AL., TETRAHEDRON LETT., vol. 42, 2001, pages 999
S. HU ET AL., J. HETEROCYCLIC. CHEM., vol. 42, 2005, pages 661

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017510610A (en) * 2014-04-11 2017-04-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Spiro [3H-indole-3,2'-pyrrolidin] -2 (1H) -one derivatives and their use as MDM2-p53 inhibitors
WO2015155332A1 (en) * 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
JP2017527532A (en) * 2014-07-03 2017-09-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel spiro [3H-indole-3,2'-pyrrolidin] -2 (1H) -one compounds and derivatives as MDM2-p53 inhibitors
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
US10576064B2 (en) 2014-07-03 2020-03-03 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
KR102627097B1 (en) 2014-08-21 2024-01-18 베링거 인겔하임 인터내셔날 게엠베하 New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
JP2017524025A (en) * 2014-08-21 2017-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel spiro [3H-indole-3,2'-pyrrolidin] -2 (1H) -one compounds and derivatives as MDM2-p53 inhibitors
KR20230098695A (en) * 2014-08-21 2023-07-04 베링거 인겔하임 인터내셔날 게엠베하 New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CN107001385A (en) * 2014-08-21 2017-08-01 勃林格殷格翰国际有限公司 Novel spiro- [ 3H-indole-3, 2' -pyrrolidine ] -2(1H) -one compounds and derivatives thereof as MDM2-P53 inhibitors
US10919913B2 (en) 2014-08-21 2021-02-16 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors
US10246467B2 (en) 2014-08-21 2019-04-02 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors
WO2016026937A1 (en) * 2014-08-21 2016-02-25 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CN107001385B (en) * 2014-08-21 2020-03-13 勃林格殷格翰国际有限公司 Spiro- [ 3H-indol-3, 2' -pyrrolidine ] -2(1H) -one compounds and derivatives thereof as MDM2-P53 inhibitors
AU2015306128B2 (en) * 2014-08-21 2020-03-26 Boehringer Ingelheim International Gmbh New spiro[3H-indole-3,2´-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors
EA038071B1 (en) * 2014-08-21 2021-07-01 Бёрингер Ингельхайм Интернациональ Гмбх SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-p53 INHIBITORS
US10144739B2 (en) 2015-10-09 2018-12-04 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
US10882866B1 (en) 2015-10-09 2021-01-05 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
US10717742B2 (en) 2015-10-09 2020-07-21 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
WO2017060431A1 (en) 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Also Published As

Publication number Publication date
US20130053410A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
US8217044B2 (en) Spiroindolinone pyrrolidines
EP2152714B1 (en) SPIROINDOLINONE DERIVATIVES AS MDM2-p53 INHIBITORS
US20120071499A1 (en) Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
EP2089360B1 (en) Spiroindolinone derivatives
EP1996591B1 (en) Spiroindolinone derivatives
US8217051B2 (en) Spiroindolinone derivatives
WO2012022707A1 (en) Substituted heteroaryl spiropyrrolidine mdm2 antagonists
US20110118283A1 (en) Substituted Pyrrolidine-2-Carboxamides
SG175756A1 (en) 3,3'-spiroindolinone derivatives and their use for cancer
CA2787304A1 (en) Substituted spiroindolinones
US7928233B2 (en) Spiroindolinone pyridine derivatives
WO2012116989A1 (en) Substituted heteroaryl 2', 3', 7', 7a' - tetrahydrospiro-[pyrrole-3, 6' - pyrrolo [1, 2-c] imidazole] - 1', 2 (1h, 5'h) -diones as anticancer agents
US20080188506A1 (en) Spiroindolinone derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12706830

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12706830

Country of ref document: EP

Kind code of ref document: A1